Pfizer Ltd

Pfizer Management Change

Pfizer Limited announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective from the close of business on September 25, 2026.

Pfizer Board Meeting Outcome

Pfizer Board approved discontinuation of Minipress XL effective September 7, 2026. The company will receive ₹131.38 Crore lump-sum payment from Pfizer Inc., USA.

Value

₹131.4 Cr

Pfizer Annual General Meeting

Pfizer Limited held its 75th Annual General Meeting on July 28, 2026. The meeting covered the adoption of financial statements, dividend declaration, and auditor remuneration ratification.

Pfizer Q1 FY27 Results: Net Profit ₹204.5 Cr, Up 6.6% YoY

Pfizer Ltd reported revenue from operations of ₹653.2 Cr (+8.3% YoY) and net profit of ₹204.5 Cr (+6.6% YoY) for Q1 FY27.

Key figure

Net profit ₹204.5 Cr · +6.6% YoY

Pfizer Management Change

Mr. Amit Agarwal has resigned as the Executive Director – Finance & Chief Financial Officer and Director of Pfizer Limited, effective October 8, 2026.

Pfizer Board Meeting Date

Pfizer Limited has scheduled a board meeting for July 28, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 2026.

Pfizer Price Movement Clarification

Pfizer clarified that Premarin Vaginal Cream's temporary discontinuation due to supply constraints has no material impact. The product contributes less than 1% of total revenue.

Pfizer Annual General Meeting

Pfizer Limited will hold its 75th AGM on July 28, 2026, via video conferencing. The agenda includes adoption of financial statements and declaration of a Rs.75/- per share dividend.

Pfizer Annual Report

Pfizer Ltd filed its Annual Report for FY 2025-26. The report highlights ₹2,520 Cr revenue and recommends a ₹75/share dividend.

Pfizer Other Announcement

Pfizer Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory compliance with SEBI and exchange listing requirements.

Pfizer Q4 FY26 Results: Net Profit ₹199.8 Cr, Down 39.6% YoY

Pfizer Ltd reported revenue from operations of ₹629.2 Cr (+6.3% YoY) and net profit of ₹199.8 Cr (-39.6% YoY) for Q4 FY26.

Key figure

Net profit ₹199.8 Cr · -39.6% YoY

Pfizer Dividend

Pfizer Limited recommended a final dividend of ₹7.5 per share for fiscal 2026. The record date is set for July 17, 2026, with payments starting August 4.

Pfizer Annual General Meeting

Pfizer Limited scheduled its 75th Annual General Meeting for July 28, 2026 via video conference. Key resolutions include dividend declaration and financial statement adoption.

Pfizer Financial Results

Pfizer Limited reported a total income of ₹2707.6 Crore for FY 2025-26. The Board also recommended a final dividend of ₹75 per equity share.

Value

₹2,708 Cr

Pfizer Board Meeting Date

Pfizer Limited has scheduled a Board Meeting for May 12, 2026, to consider and approve financial results for the quarter and year ended March 31, 2026. The board will also consider a dividend recommendation. The company's trading window remains closed until May 14, 2026.

Pfizer Board Meeting Date

Pfizer Limited has scheduled a board meeting for May 12, 2026. The board will consider and approve audited standalone financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 14, 2026.

Pfizer Board Meeting Date

Pfizer Limited has scheduled a board meeting on May 12, 2026, to consider and approve audited standalone financial results for the year ended March 31, 2026. The board will also recommend a final dividend for the financial year 2025-26. The trading window remains closed until May 14, 2026.

Pfizer Legal & Regulatory

Pfizer Ltd received an Income-tax Assessment Order and a tax demand of ₹85.74 Crore for FY 2022-23 due to alleged under-reporting of income. The company is also facing penalty proceedings. Pfizer believes it has strong grounds on merits and does not expect a material impact on its financial position at this stage.

Value

₹85.74 Cr

Pfizer Results Correction

Pfizer Limited clarified a technical error in its XBRL submission for the quarter ended September 30, 2025. Following National Stock Exchange guidance, the company re-filed the Integrated Filing - Financials, correcting the 'Reporting Quarter' selection from 'Half Year' to 'Second quarter'. The revised filing is now correctly reflected on the NSE website.